MERCURY I

Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy. A study assessing the effect of switching to low-dose rosuvastatin from atorvastatin, simvastatin and pravastatin on LDL cholesterol in patients requiring lipid-lowering therapy
Conclusion More patients who switched from other agents to rosuvastatin achieved their LDL-cholesterol goal. Rosuvastatin reduced LDL cholesterol and triglycerides, and raised HDL cholesterol more than the other agents. All statins were well tolerated
References in periodicals archive ?
DFJ Mercury is a seed and early-stage venture capital firm focusing on investment opportunities in the midcontinent.